潤達醫療(603108.SH):基於慧檢產品開發基礎結合華為盤古大模型技術開發的普惠AI醫療大模型產品即將正式發佈
格隆匯9月12日丨有投資者向潤達醫療(603108.SH)提問:公司基於華為盤古大模型開發的醫療AI大模型B端已經在多少家醫院運營?運營效果如何?目前正在談或者跟蹤的醫療機構多少家?今明兩年計劃拓展到多少家?謝謝。
潤達醫療回覆:尊敬的投資者您好!目前公司開發的慧檢產品已在國內40餘家醫療機構推廣使用,得到用户較好的評價和認可。基於慧檢產品開發基礎結合華為盤古大模型技術開發的普惠AI醫療大模型產品即將正式發佈,後續會積極推向市場。感謝您的關注。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.